Trials / Terminated
TerminatedNCT05409183
Effectiveness of CRD-740 in Heart Failure
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Cardurion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to placebo in plasma cGMP at Week 4 in HFrEF. Part B of the study was not conducted in favor of redesigned new studies.
Conditions
- Heart Failure
- Heart Failure With Reduced Ejection Fraction
- Heart Failure With Preserved Ejection Fraction
- Cardiovascular Diseases
- Heart Diseases
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CRD-740 | Tablets administered orally. |
| DRUG | Placebo | Tablets administered orally. |
Timeline
- Start date
- 2022-05-26
- Primary completion
- 2023-05-02
- Completion
- 2023-07-25
- First posted
- 2022-06-08
- Last updated
- 2024-12-19
- Results posted
- 2024-12-19
Locations
34 sites across 4 countries: United States, Canada, Israel, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05409183. Inclusion in this directory is not an endorsement.